麻豆女优

Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Medicaid Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • 麻豆女优 Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Emergency Room Boarding
  • Device Coverage by Medicare
  • Planned Parenthood Funding
  • Covid/Flu Combo Shot
  • RFK Jr. vs. Congress

TRENDING TOPICS:

  • Emergency Room Boarding
  • Device Coverage by Medicare
  • Planned Parenthood Funding
  • Covid/Flu Combo Shot
  • RFK Jr. vs. Congress

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Thursday, Jun 4 2015

Full Issue

Diabetics Encounter Obstacles To Obtaining 'Breakthrough' Inhaled Insulin Option

Early sales of MannKind Corp.'s new insulin drug Afrezza, that is delivered through an inhalation device, are disappointing as patient adoption has been slow due to factors like doctor reluctance to prescribe and an FDA-mandated lung test. In other pharma news, a provision of the health law establishing a pathway for biosimilars may save patients as much as $800 a month in co-pays.

It took 10 years and $1 billion for MannKind Corp. in Valencia to get its breakthrough inhaled-insulin drug approved by U.S. regulators. Now comes the hard part: getting people with diabetes to use it. If Cynthia Goldstein's experience is any indication, it's not going to be easy. (Pfeifer, 6/3)

It's no secret that health care costs are on the rise, and have been for years. From monthly premiums to co-pays and now coinsurance for prescription drugs, consumers are being squeezed financially as a result of trying to keep their families healthy. A relatively new factor in this cost-versus-care debate are biologic drugs, complex medicines made from living cells that treat deadly and debilitating diseases. Doctors are increasingly prescribing them to treat everything from cancer to rheumatoid arthritis to multiple sclerosis. (Greenberg, 6/3)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, April 27
  • Friday, April 24
  • Thursday, April 23
  • Wednesday, April 22
  • Tuesday, April 21
  • Monday, April 20
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Republish Our Content
  • Contact Us

Follow Us

  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

漏 2026 麻豆女优